Literature DB >> 21553651

PDE4 inhibitor suppresses PGE2-induced osteoclast formation via COX-2-mediated p27(KIP1) expression in RAW264.7 cells.

Ling Chen1, Ting Zheng, Hyojung Park, A Long Sae Mi Noh, Jung-Min Lee, Dong-Seok Lee, Mijung Yim.   

Abstract

We investigated the effects of phosphodiesterase 3 (PDE3) and PDE4 inhibitors, which are cAMP degrading enzymes, on prostaglandin E2 (PGE2)-induced osteoclast formation. A PDE4 inhibitor decreased PGE2-induced osteoclast formation, whereas a PDE3 inhibitor did not, possibly due to the lack of PDE3 expression in RAW 264.7 cells. Cell cycle analysis revealed that the PDE4 inhibitor stimulated PGE2-induced p27(KIP1) expression, which leads to increased growth arrest at G0/G1 phase. The PDE4 inhibitor increased cyclooxygenase 2 (COX-2) expression in the presence of PGE2. COX-2 overexpression was associated with growth suppression via p27(KIP1) expression in RAW 264.7 cells. Taken together, our data demonstrate that the PDE4 inhibitor enhances PGE2-induced growth arrest of osteoclast precursors via COX-2-mediated p27(KIP1) expression, which in turn negatively regulates osteoclast formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553651

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  1 in total

1.  IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.

Authors:  Tue W Kragstrup; Mary Adams; Søren Lomholt; Morten A Nielsen; Line D Heftdal; Peter Schafer; Bent Deleuran
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-02-22       Impact factor: 5.346

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.